Edesa Biotech, Inc. financial data

Symbol
EDSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Spy Court, Markham, Ontario, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
September 30
Former names
Stellar Biotechnologies, Inc. (to 5/30/2019)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 230 % -54.9%
Debt-to-equity 41.5 % +122%
Return On Equity -138 % -33%
Return On Assets -97.5 % -11.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.25M shares -84.6%
Common Stock, Shares, Outstanding 3.25M shares -84.4%
Entity Public Float 0 USD
Common Stock, Value, Issued 47.2M USD +2.37%
Weighted Average Number of Shares Outstanding, Basic 3.22M shares +9.93%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.73M USD -33.8%
General and Administrative Expense 4.65M USD +14.7%
Operating Income (Loss) -8.38M USD +13.5%
Nonoperating Income (Expense) 1.45M USD +554%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.67M USD +16%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -6.93M USD +26.8%
Earnings Per Share, Basic -0.52 USD/shares +23.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.4M USD -23.8%
Assets, Current 3.05M USD -55.9%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 36.3K USD -67.7%
Intangible Assets, Net (Excluding Goodwill) 2.21M USD
Assets 5.23M USD -44.5%
Liabilities, Current 2.36M USD +54.4%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 2.36M USD +50.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -225K USD -18.2%
Retained Earnings (Accumulated Deficit) -57.6M USD -13.7%
Stockholders' Equity Attributable to Parent 2.87M USD -63.5%
Liabilities and Equity 5.23M USD -44.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.41M USD +21.5%
Net Cash Provided by (Used in) Financing Activities 306K USD -89.5%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares, Issued 3.25M shares -84.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.09M USD -193%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.04M USD -68.4%
Deferred Tax Assets, Valuation Allowance 16.5M USD +9.1%
Deferred Tax Assets, Gross 16.7M USD +10.4%
Operating Lease, Liability 38.8K USD -66.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.96M USD +27%
Lessee, Operating Lease, Liability, to be Paid 39.6K USD -67.7%
Property, Plant and Equipment, Gross 52.5K USD +0.64%
Operating Lease, Liability, Current 38.8K USD -48.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20K USD -0.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.8K USD -75.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 745 USD
Additional Paid in Capital 13.5M USD +7.02%
Operating Leases, Future Minimum Payments, Due in Two Years 79.9K USD +28.3%
Amortization of Intangible Assets 30K USD 0%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 59.9K USD
Deferred Tax Assets, Net of Valuation Allowance 233K USD +547%
Operating Leases, Future Minimum Payments, Due in Three Years 20K USD -3.78%
Operating Leases, Future Minimum Payments Due 160K USD +92.4%